Literature DB >> 7626579

Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.

J P Diamond1, L White, J P Leeming, H Bing Hoh, D L Easty.   

Abstract

AIMS: This study was designed to assess the relative corneal penetration of topical drops of three antibiotics and to relate those levels to minimum inhibitory concentrations for organisms associated with bacterial keratitis.
METHODS: Four drops of each of ciprofloxacin, norfloxacin, and ofloxacin (0.3% topical ophthalmic preparations) were given to 12 patients undergoing corneal transplantation. After the recipient tissue was removed, corneal drug penetration was measured using high performance liquid chromatography.
RESULTS: Intracorneal concentrations of ofloxacin (geometric mean 0.81 mg kg-1) were significantly higher than both ciprofloxacin (0.60 mg kg-1; p = 0.048) and norfloxacin (0.54 mg kg-1; p = 0.012). Ciprofloxacin and norfloxacin concentrations did not differ significantly (p = 0.33).
CONCLUSIONS: Review of the minimum inhibitory concentrations of the fluoroquinolones against ocular pathogens reveals that ciprofloxacin is more potent than ofloxacin against many bacteria; ofloxacin is in turn more potent than norfloxacin. These data favour the selection of ciprofloxacin and ofloxacin rather than norfloxacin for the empirical treatment of corneal infection. The greater potency of ciprofloxacin offsets the superior penetration of ofloxacin. There is a need for improved clinical trial data concerning the use of fluoroquinolone eyedrops in ulcerative keratitis; some encouraging data are available for ciprofloxacin but not (in humans) for norfloxacin or ofloxacin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7626579      PMCID: PMC505175          DOI: 10.1136/bjo.79.6.606

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis.

Authors:  H M Leibowitz
Journal:  Am J Ophthalmol       Date:  1991-10       Impact factor: 5.258

2.  Topical ofloxacin in the treatment of Pseudomonas keratitis in a rabbit model.

Authors:  D C Gritz; P J McDonnell; T Y Lee; D Tang-Liu; B B Hubbard; A Gwon
Journal:  Cornea       Date:  1992-03       Impact factor: 2.651

3.  Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor.

Authors:  E D Donnenfeld; A Schrier; H D Perry; T Aulicino; M E Gombert; R Snyder
Journal:  Ophthalmology       Date:  1994-05       Impact factor: 12.079

4.  The comparative in vitro activity of ofloxacin and selected ophthalmic antimicrobial agents against ocular bacterial isolates.

Authors:  M S Osato; H G Jensen; M D Trousdale; J A Bosso; L R Borrmann; J Frank; P Akers
Journal:  Am J Ophthalmol       Date:  1989-10-15       Impact factor: 5.258

Review 5.  Microbiologic aspects of fluoroquinolones.

Authors:  H C Neu
Journal:  Am J Ophthalmol       Date:  1991-10       Impact factor: 5.258

6.  The comparative in-vitro activity of ofloxacin.

Authors:  R N Grüneberg; D Felmingham; M D O'Hare; M J Robbins; K Perry; R A Wall; G L Ridgway
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

7.  Corneal stromal penetration of topical ciprofloxacin in humans.

Authors:  M L McDermott; T D Tran; J W Cowden; C J Buggé
Journal:  Ophthalmology       Date:  1993-02       Impact factor: 12.079

8.  In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.

Authors:  N X Chin; A Novelli; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

9.  Ulcerative keratitis associated with contact lens wear.

Authors:  A Koidou-Tsiligianni; E Alfonso; R K Forster
Journal:  Am J Ophthalmol       Date:  1989-07-15       Impact factor: 5.258

10.  In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.

Authors:  A L Barry; R N Jones
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

View more
  13 in total

1.  Penetration of topical, oral, and combined administered ofloxacin into the subretinal fluid.

Authors:  O Cekiç; C Batman; U Yasar; Y Totan; N E Basci; A Bozkurt; O Zilelioglu; S O Kayaalp
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

2.  In vitro antibiotic resistance in bacterial keratitis in London.

Authors:  S J Tuft; M Matheson
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

Review 3.  Comparative review of topical ophthalmic antibacterial preparations.

Authors:  P Y Robert; J P Adenis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Suppurative keratitis.

Authors:  S J Tuft
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

5.  In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10-year review.

Authors:  H O Orlans; S J Hornby; I C J W Bowler
Journal:  Eye (Lond)       Date:  2011-01-21       Impact factor: 3.775

6.  Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops.

Authors:  Mahendra Singh Rathore; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2006-07-07       Impact factor: 3.246

Review 7.  Treatment of ocular infections with topical antibacterials.

Authors:  J P Leeming
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 8.  Fluoroquinolones: place in ocular therapy.

Authors:  A Smith; P M Pennefather; S B Kaye; C A Hart
Journal:  Drugs       Date:  2001       Impact factor: 9.546

9.  Ciprofloxacin as ocular liposomal hydrogel.

Authors:  Khaled Mohamed Hosny
Journal:  AAPS PharmSciTech       Date:  2010-02-12       Impact factor: 3.246

10.  Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.

Authors:  Tuomo Puustjärvi; Markku Teräsvirta; Pila Nurmenniemi; Jukka Lokkila; Hannu Uusitalo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.